|
|
Post by Clement on Sept 10, 2019 8:05:54 GMT -5
|
|
paul
Researcher
Posts: 134
|
Post by paul on Sept 10, 2019 9:09:09 GMT -5
I hope they plan on having more than just that one site.
|
|
|
|
Post by hellodolly on Sept 10, 2019 9:21:08 GMT -5
I hope they plan on having more than just that one site. It's only a 9 month study with patients already using Tyvaso, I'm not sure it needs more sites. |
|
|
|
Post by Clement on Sept 10, 2019 11:00:35 GMT -5
Does the fact that the BREEZE study is now officially recruiting have an impact on timing of the next milestone payment of $12.5M?
|
|
|
|
Post by Clement on Sept 11, 2019 8:14:46 GMT -5
In SO's article of today, he indicates in his revenue/cash-burn chart that he assumes United Therapeutics will pay the $12.5M milestone in this month (Sept.).
seekingalpha.com/article/4290855-mannkind-investor-conference-scripts-story-evolving
|
|
|
|
Post by matt on Sept 11, 2019 8:51:56 GMT -5
Does the fact that the BREEZE study is now officially recruiting have an impact on timing of the next milestone payment of $12.5M? There are two sets of milestone payments, one for TreT and one for the "undisclosed" molecule. These are two completely separate initiatives and the progress on one drug does not help or hurt progress on the other. The next milestone payment expected is for the undisclosed molecule, not TreT, at the decision of whether to progress the mystery drug to the next stage rests with UTHR. This is common with drug licensing deals; the licensor is writing the checks and thus controls most of the decisions and, ultimately, the timing. |
|
|
|
Post by Clement on Sept 11, 2019 8:56:56 GMT -5
Does the fact that the BREEZE study is now officially recruiting have an impact on timing of the next milestone payment of $12.5M? There are two sets of milestone payments, one for TreT and one for the "undisclosed" molecule. These are two completely separate initiatives and the progress on one drug does not help or hurt progress on the other. The next milestone payment expected is for the undisclosed molecule, not TreT, at the decision of whether to progress the mystery drug to the next stage rests with UTHR. This is common with drug licensing deals; the licensor is writing the checks and thus controls most of the decisions and, ultimately, the timing. The way I see it is: next TreT milestone and the number in SO's article today --- $12.5M first "undisclosed" molecule milestone, if any --- $15M |
|
|
|
Post by prcgorman2 on Sept 11, 2019 9:07:36 GMT -5
Well, that answers the FUD'sters who were trying to suggest TreT may not move forward in a trial after all. Dr. Rothblatt even said at Wedbush that they had discussed this trial using existing Tyvaso patients with the FDA. But the shorts never miss an opportunity to sow fear, uncertainty, and doubt.
|
|
|
|
Post by mytakeonit on Sept 11, 2019 12:24:38 GMT -5
I have no doubt, fear, or uncertainty ... that my E*Trade account is growing by leaps and bounds.
But, that's mytakeonit
|
|
|
|
Post by alethea on Sept 11, 2019 23:25:15 GMT -5
Does the fact that the BREEZE study is now officially recruiting have an impact on timing of the next milestone payment of $12.5M? There are two sets of milestone payments, one for TreT and one for the "undisclosed" molecule. These are two completely separate initiatives and the progress on one drug does not help or hurt progress on the other. The next milestone payment expected is for the undisclosed molecule, not TreT, at the decision of whether to progress the mystery drug to the next stage rests with UTHR. This is common with drug licensing deals; the licensor is writing the checks and thus controls most of the decisions and, ultimately, the timing. No, I think the above is not correct. MNKD is getting $25M per year for TreT for both 2018 and 2019 which is paid in two installments of $12.5M in each year. MNKD is yet to receive the 2nd installment for TreT for 2019 but should receive it before the end of this year. Spencer O schedules it in September in his latest article. The payment for the "undisclosed molecule" of $15M (if memory serves) is as yet undetermined or at least undisclosed. Should this be announced soon it will be in addition to the $12.5M and further enhance MNKD's much improved cash position and extend its runway. As some have already noted even Spencer O has turned positive. Likely to avoid looking foolish now that MNKD has a vastly improved future outlook. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 12, 2019 0:44:54 GMT -5
There are two sets of milestone payments, one for TreT and one for the "undisclosed" molecule. These are two completely separate initiatives and the progress on one drug does not help or hurt progress on the other. The next milestone payment expected is for the undisclosed molecule, not TreT, at the decision of whether to progress the mystery drug to the next stage rests with UTHR. This is common with drug licensing deals; the licensor is writing the checks and thus controls most of the decisions and, ultimately, the timing. No, I think the above is not correct. MNKD is getting $25M per year for TreT for both 2018 and 2019 which is paid in two installments of $12.5M in each year. MNKD is yet to receive the 2nd installment for TreT for 2019 but should receive it before the end of this year. Spencer O schedules it in September in his latest article. The payment for the "undisclosed molecule" of $15M (if memory serves) is as yet undetermined or at least undisclosed. Should this be announced soon it will be in addition to the $12.5M and further enhance MNKD's much improved cash position and extend its runway. As some have already noted even Spencer O has turned positive. Likely to avoid looking foolish now that MNKD has a vastly improved future outlook. Milestone payments are for 2019 & 2020. |
|
|
|
Post by prcgorman2 on Sept 12, 2019 8:51:38 GMT -5
Huh? Already received some.
|
|
|
|
Post by ktim on Sept 16, 2019 15:01:35 GMT -5
There are two sets of milestone payments, one for TreT and one for the "undisclosed" molecule. These are two completely separate initiatives and the progress on one drug does not help or hurt progress on the other. The next milestone payment expected is for the undisclosed molecule, not TreT, at the decision of whether to progress the mystery drug to the next stage rests with UTHR. This is common with drug licensing deals; the licensor is writing the checks and thus controls most of the decisions and, ultimately, the timing. No, I think the above is not correct. MNKD is getting $25M per year for TreT for both 2018 and 2019 which is paid in two installments of $12.5M in each year. MNKD is yet to receive the 2nd installment for TreT for 2019 but should receive it before the end of this year. Spencer O schedules it in September in his latest article. The payment for the "undisclosed molecule" of $15M (if memory serves) is as yet undetermined or at least undisclosed. Should this be announced soon it will be in addition to the $12.5M and further enhance MNKD's much improved cash position and extend its runway. As some have already noted even Spencer O has turned positive. Likely to avoid looking foolish now that MNKD has a vastly improved future outlook. If he has been negative for the time period when MNKD shares lost a huge portion of their value and then calls it right on the final turn around, he will look like a genius compared to most people opining about MNKD (myself included). But regardless of the whether he's right on the turnaround, he deserves credit for being the correct one up until now. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 16, 2019 16:49:12 GMT -5
Huh? Already received some. Yes they have received Milestone #1. They have 3 more coming before EOY 2020. |
|
|
|
Post by harryx1 on Sept 27, 2019 9:44:35 GMT -5
|
|
